Wu Jianhui, Male, Han Nationality, member of Communist Party of China, born in Xingan County, Ji’an City of Jiangxi Province in July 1976, Doctor of Pharmacology, a researcher and a postgraduate tutor in School of Pharmacy of Fudan University. Now, he takes the post of Deputy Director in the Department of Pharmacology &Toxicology of Shanghai Institute of Planned Parenthood Research (SIPPR) and party branch secretary. His research mainly focuses on pharma-toxicology of prostate diseases, male reproductive health and non-clinical safety evaluation on new drugs; moreover, critical fields that he focuses on consist of benign prostatic hyperplasia occurrence mechanism and R & D of relevant drugs.
       He used to preside over a project named as Study on Relationship between Environmental Endocrine Disruptors BPA and BPH supported by the National Natural Science Foundation of China, another project named as Study on Relationship and Mechanism of Estrogen Active Endocrine Disruptor and BPH supported by the Talent Development Fund of Shanghai and another project named as A Professional Technical Service Platform for Non-clinical Evaluations on Drugs Against Male Reproductive and Urinary Diseases in Shanghai supported by Science and Technology Commission of Shanghai Municipality, also acts as deputy chief of a major special project of science and technology known as “Creation of Major New Drugs” (Establish a Non-clinical Safety Evaluation Technology Platform up to International New Drug Development Specifications) supported by the Ministry of Science and Technology, and takes charge of contents construction for the project named as Establish a Non-clinical Safety Evaluation Management and Application System up to International New Drug Development Specifications. Additionally, he also participates in 10 ministerial and provincial subjects as a core member (ranking top three) to preside over research about BPH, including in vitro and in vivo model building, methodology validation and mechanism exploring, etc., and complete safety evaluations on over 60 items of 28 varieties of drug and pharmacodynamics studies on 16 drugs against BPH.
       He once won RASS scholarship to study in 11th Risk Assessment Summer School held by the International Union of Toxicology (IUTOX) in Germany. Besides, he was listed into the Talent Development Funding Scheme of Shanghai, won the second prize of the Science and Technology Progress Award of Shanghai (ranking third, name of the project is Pharma-toxicological Study on BPH and the Application), the third prize of the Science and Technology Progress Award of Shanghai (ranking second, name of the project is Cervical Erosion Control Technology and Product Development), the second prize of Huaxia Medical Science and Technology Award (ranking second, name of the project is Establishment and Application of a Non-clinical Evaluation System for Prostate Diseases), the second prize of the Science and Technology Award endowed by the Chinese Association for Laboratory Animal Sciences (CALAS) (ranking third, name of the project is Establishment and Application of a Biological Model for Prostate Diseases), the third prize of the Science and Technology Award endowed by Chinese Pharmaceutical Association (CPA) (ranking second, name of the project is Establishment and Application of a Non-clinical Evaluation System for Drugs Against Male Reproductive and Urinary Diseases), Travel Prize for Senior Scientists awarded by IUTOX CTDC and the Award of Excellent Young Scientific and Technological Talent endowed on the 1st conference of Chinese Society of Toxicology. As the principal inventor, he has applied for 4 patents for scientific and technological invention, among which, 2 have been authorized and 1 acquired a software copyright certificate. Additionally, he has published more than 100 papers and 20 have been incorporated into SCI journals and 50 into Chinese core periodicals. The number of academic monographs that he co-edits is 4, including Prostate Pharmacology.  
       He acts as an expert in Center for Drug Evaluation of China Food and Drug Administration (CFDA), a communication review expert in the National Natural Science Foundation of China, a standing member of Youth Committee of Chinese Society of Toxicology, a member of Committee on Clinical Research Statistics of the World Federation of Chinese Medicine Societies (WFCMS), a member in of Quality Assurance in Toxicology Research Research, Chinese Society of Toxicology, a member in Committee on Reproductive Pharmacology of Chinese Pharmacological Society, a member of Committee of Mutagenesis of Chinese Environmental Mutagen Society, a member of Committee of Alternatives Methods and Translational Toxicology，Chinese Society of Toxicology, a member in Committee of Drug Safety Evaluation Researches of Chinese Pharmacological Society, a member of Committee of Toxicology of Shanghai Pharmacological Society, a member of Committee of  Experimental Animal Ethical Welfare of Shanghai Lab. Animal Society, a member of the Committee of Experimental Animal Industrialization of Shanghai Lab. Animal Society, a member of Committee of Experimental Animal Ethics of Shanghai Institute of Planned Parenthood Research (SIPPR), a contributing reviewer of Acta Laboratorium Animalis Scientia Sinica and Chinese Journal of Comparative Medicine, and a contributing correspondent of China’s Toxicology Communication, etc..